Fenwick Represents Belharra Therapeutics in Strategic Collaboration with Sanofi

Fenwick represented Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, in its strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases. The collaboration will leverage Belharra’s proprietary non-covalent chemoproteomics platform to screen and validate hits against undisclosed Sanofi-designated immunology targets.

Under the terms of the agreement, Belharra is eligible to receive up to $40 million in upfront and near-term milestone payments, with a potential total deal value of up to nearly $700 million in payments over the course of the collaboration in research, development, and commercial milestones, as well as tiered royalties on net sales. More information about the collaboration can be obtained from Belharra Therapeutics' announcement.

The Fenwick transaction team was led by Life Sciences partner Stefano Quintini and included Leanne Ta and Jake Handy.